title: Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.
authors.affiliation: Cyclacel Limited, Dundee DD15JJ, Scotland, UK.
authors.forename: Shudong
authors.initials: S
authors.lastname: Wang
authors.forename: Gary
authors.initials: G
authors.lastname: Griffiths
authors.forename: Carol A
authors.initials: CA
authors.lastname: Midgley
authors.forename: Anna L
authors.initials: AL
authors.lastname: Barnett
authors.forename: Michael
authors.initials: M
authors.lastname: Cooper
authors.forename: Joanna
authors.initials: J
authors.lastname: Grabarek
authors.forename: Laura
authors.initials: L
authors.lastname: Ingram
authors.forename: Wayne
authors.initials: W
authors.lastname: Jackson
authors.forename: George
authors.initials: G
authors.lastname: Kontopidis
authors.forename: Steven J
authors.initials: SJ
authors.lastname: McClue
authors.forename: Campbell
authors.initials: C
authors.lastname: McInnes
authors.forename: Janice
authors.initials: J
authors.lastname: McLachlan
authors.forename: Christopher
authors.initials: C
authors.lastname: Meades
authors.forename: Mokdad
authors.initials: M
authors.lastname: Mezna
authors.forename: Iain
authors.initials: I
authors.lastname: Stuart
authors.forename: Mark P
authors.initials: MP
authors.lastname: Thomas
authors.forename: Daniella I
authors.initials: DI
authors.lastname: Zheleva
authors.forename: David P
authors.initials: DP
authors.lastname: Lane
authors.forename: Robert C
authors.initials: RC
authors.lastname: Jackson
authors.forename: David M
authors.initials: DM
authors.lastname: Glover
authors.forename: David G
authors.initials: DG
authors.lastname: Blake
authors.forename: Peter M
authors.initials: PM
authors.lastname: Fischer
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000627:therapeutic use; D017209:Apoptosis; D001665:Binding Sites; D045744:Cell Line, Tumor; D003198:Computer Simulation; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D051379:Mice; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000627:therapeutic use; D011743:Pyrimidines / Q000737:chemistry* / Q000627:therapeutic use; D014158:Transcription, Genetic / Q000187:drug effects; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D016159:Tumor Suppressor Protein p53; D018844:Cyclin-Dependent Kinases